USPTO published patent application US20260092922A1 on April 2, 2026, disclosing methods and compositions for diagnosing biochemical recurrence (BCR) in prostate cancer through biomarker detection. Application No. 19207308 was filed May 13, 2025, listing 9 inventors including Michael Kiebish and colleagues. The claimed invention includes diagnostic methods and kits/panels for detecting BCR biomarkers.

This publication does not create new regulatory obligations. Entities conducting prostate cancer diagnostics, biomarker research, or developing related diagnostic kits should review the claims to assess potential patent landscape implications, freedom-to-operate concerns, or licensing opportunities. No compliance deadline or enforcement action applies to this document.